Characterization of the Expression of BTN1A1 exclusive to PD-L1PD-1 axis in Small Cell Lung Cancer using Spatial Biology Approach

A phase I study of Nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumor

Pharmacokinetic Analyses and Immunophenotyping of Patients Treated With Nelmastobart (hSTC810), A Novel Immune Checkpoint Inhibitor

Development of Diagnostic Antibodies For Anti-BTN1A1 Therapy, A Novel Immune Checkpoint Inhibitor Mutually Exclusive of PD-1/PD-L1 axis

A first-in human trial of hSTC810 (anti-BTN1A1 monoclonal antibody), targeting a novel immune checkpoint with a mutually exclusive expression with PD-1PD-L1 in patients with relapsed/refractory solid tumors

Anti-BTN1A1 exhibits synergistic anti-tumor immunotherapeutic efficacy in combination with radiation therapy

Humanized STC810 is a Monoclonal Antibody to BTN1A1, a Novel Immunotherapeutic Target to be Evaluated in a Planned Phase 1 Study

Targeting BTN1A1, an upstream regulator of PD-L1, as an alternative strategy in cancer immunotherapy

BTN1A1: A Novel Immune Checkpoint For Cancer Immunotherapy Beyond The PD-1/PD-L1 Axis